Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 66% of modeled bridge. Strengths: Commercial Payer %, Bed Count. Risks: Revenue per Bed, Occupancy Rate. Risk-adjusted uplift: $0.4M (vs $0.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $211K | $8K | $219K | $0 | 12mo |
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $219K | $219K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $34K | $100K | $133K | $421K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 49.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | $0 | $55K | $110K | $165K | $219K | $219K | $219K | $219K |
| Cost to Collect | $0 | $55K | $110K | $165K | $219K | $219K | $219K | $219K |
| A/R Days Reduction | $0 | $44K | $89K | $133K | $133K | $133K | $133K | $133K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $159K | $318K | $472K | $582K | $582K | $582K | $582K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $582K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 70% / 14.4x | 75% / 16.3x | 79% / 18.3x | 81% / 19.3x | 82% / 20.2x |
| 9.0x | 66% / 12.4x | 70% / 14.2x | 74% / 15.9x | 76% / 16.8x | 78% / 17.6x |
| 10.0x | 61% / 10.8x | 66% / 12.4x | 69% / 14.0x | 71% / 14.8x | 73% / 15.6x |
| 11.0x | 57% / 9.6x | 62% / 11.0x | 66% / 12.4x | 67% / 13.1x | 69% / 13.8x |
| 12.0x | 53% / 8.5x | 58% / 9.8x | 62% / 11.1x | 64% / 11.8x | 66% / 12.4x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 42% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 3.8x, adding 4.7 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $465K | — | $465K | 4.2% |
| Year 1 | $479K | +$388K | $867K | 7.9% |
| Year 2 | $494K | +$582K | $1.1M | 9.8% |
| Year 3 | $508K | +$582K | $1.1M | 9.9% |
| Year 4 | $524K | +$582K | $1.1M | 10.1% |
| Year 5 | $539K | +$582K | $1.1M | 10.2% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Denial Rate Reductio | $110K | $165K | $219K | $263K |
| Cost to Collect | $110K | $165K | $219K | $263K |
| A/R Days Reduction | $67K | $100K | $133K | $160K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $291K | $436K | $582K | $698K |
Peer Context — Where This Hospital Sits
Key metrics vs 76 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 4.2% | -8.8% | -3.0% | 5.4% | P72 |
| Net-to-Gross | 47.2% | 33.4% | 42.7% | 49.2% | P66 |
| Occupancy | 44.9% | 19.4% | 28.3% | 42.6% | P79 |
| Rev/Bed | $323K | $989K | $1.4M | $2.0M | P3 |
| Exp/Bed | $309K | $1.2M | $1.5M | $2.0M | P1 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.